These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 36094645)

  • 1. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
    Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
    JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
    Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
    JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
    JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donanemab in Early Alzheimer's Disease.
    Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
    N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
    Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
    Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
    Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
    Lowe SL; Duggan Evans C; Shcherbinin S; Cheng YJ; Willis BA; Gueorguieva I; Lo AC; Fleisher AS; Dage JL; Ardayfio P; Aguiar G; Ishibai M; Takaichi G; Chua L; Mullins G; Sims JR
    J Prev Alzheimers Dis; 2021; 8(4):414-424. PubMed ID: 34585215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Still grasping at straws: donanemab in Alzheimer's disease.
    Doggrell SA
    Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial.
    Edwards AL; Collins JA; Junge C; Kordasiewicz H; Mignon L; Wu S; Li Y; Lin L; DuBois J; Hutchison RM; Ziogas N; Shulman M; Martarello L; Graham D; Lane R; Budd Haeberlein S; Beaver J
    JAMA Neurol; 2023 Dec; 80(12):1344-1352. PubMed ID: 37902726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How donanemab data address the coverage with evidence development questions.
    Klein EG; Schroeder K; Wessels AM; Phipps A; Japha M; Schilling T; Zimmer JA
    Alzheimers Dement; 2024 Apr; 20(4):3127-3140. PubMed ID: 38323738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
    Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
    JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.
    Aksman LM; Oxtoby NP; Scelsi MA; Wijeratne PA; Young AL; Alves IL; Collij LE; Vogel JW; Barkhof F; Alexander DC; Altmann A;
    Brain; 2023 Dec; 146(12):4935-4948. PubMed ID: 37433038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
    Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Wang J; Shcherbinin S; Sims JR; Chigutsa E
    Alzheimers Dement (N Y); 2023; 9(2):e12404. PubMed ID: 37388759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
    Wessels AM; Dennehy EB; Dowsett SA; Dickson SP; Hendrix SB
    Neurol Clin Pract; 2023 Apr; 13(2):e200127. PubMed ID: 36891463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.
    Yu L; Petyuk VA; Tasaki S; Boyle PA; Gaiteri C; Schneider JA; De Jager PL; Bennett DA
    JAMA Neurol; 2019 Jul; 76(7):818-826. PubMed ID: 31009033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment.
    Insel PS; Hansson O; Mattsson-Carlgren N
    JAMA Neurol; 2021 Feb; 78(2):229-235. PubMed ID: 33044487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
    Ross EL; Weinberg MS; Arnold SE
    JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
    Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
    Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
    Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
    JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
    Teng E; Manser PT; Pickthorn K; Brunstein F; Blendstrup M; Sanabria Bohorquez S; Wildsmith KR; Toth B; Dolton M; Ramakrishnan V; Bobbala A; Sikkes SAM; Ward M; Fuji RN; Kerchner GA;
    JAMA Neurol; 2022 Aug; 79(8):758-767. PubMed ID: 35696185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.